INCY
Incyte Corporation · Healthcare
Insiders sold $36.4M of Incyte Corporation in the last 12 months and bought none
INCY over the last year
INCY after insider buys
3 months after each buy, from the first price a copier could get.
3 buys since 2017 with 3 months of prices.
Congress
Members reported 18 trades in INCY since 2023.
Every filing
205 insider filings since 2016, newest first
Jonathan Elliott Dickinson · EVP, GM, Europe
Paula J Swain · EVP and HR
Paul Trower · Principal Accounting Officer
Paula J Swain · EVP and HR
Wendy L Dixon · Director
Dashyant Dhanak · EVP and Chief Scientific Officer
Dashyant Dhanak · EVP and Chief Scientific Officer
Dashyant Dhanak · EVP and Chief Scientific Officer
Vijay K Iyengar · EVP GPS, BD, Licensing
Dashyant Dhanak · EVP and Chief Scientific Officer
Yao Wenqing · EVP, Head of Discovery Chem
Dashyant Dhanak · EVP and Chief Scientific Officer
Dashyant Dhanak · EVP and Chief Scientific Officer
Dashyant Dhanak · EVP and Chief Scientific Officer
Dashyant Dhanak · EVP and Chief Scientific Officer
Michael James Morrissey · EVP, Head of Tech. Operations
Dashyant Dhanak · EVP and Chief Scientific Officer
Herve Hoppenot · Chair and CEO
Dashyant Dhanak · EVP and Chief Scientific Officer
Steven H Stein · EVP and Chief Medical Officer
Yao Wenqing · EVP, Head of Discovery Chem
Vijay K Iyengar · EVP GPS, BD, Licensing
Barry P Flannelly · EVP, GM US
Jean Jacques Bienaime · Director
Dashyant Dhanak · EVP and Chief Scientific Officer
Barry P Flannelly · EVP, GM US
Maria E Pasquale · EVP and General Counsel
Dashyant Dhanak · EVP and Chief Scientific Officer
Maria E Pasquale · EVP and General Counsel
Dashyant Dhanak · EVP and Chief Scientific Officer
Wendy L Dixon · Director
Dashyant Dhanak · EVP and Chief Scientific Officer
Steven H Stein · EVP and Chief Medical Officer
Steven H Stein · EVP and Chief Medical Officer
Vijay K Iyengar · EVP GPS, BD, Licensing
Steven H Stein · EVP and Chief Medical Officer
Yao Wenqing · EVP, Head of Discovery Chem
Herve Hoppenot · Chair and CEO
Dashyant Dhanak · EVP and Chief Scientific Officer
Herve Hoppenot · Chair and CEO
Paul Trower · Principal Accounting Officer
Barry P Flannelly · EVP, GM US
Maria E Pasquale · EVP and General Counsel
Vijay K Iyengar · EVP GPS, BD, Licensing
Barry P Flannelly · EVP, GM US
Jonathan Elliott Dickinson · EVP, GM, Europe
Maria E Pasquale · EVP and General Counsel
Dashyant Dhanak · EVP and Chief Scientific Officer
Dashyant Dhanak · EVP and Chief Scientific Officer
Paul Trower · Principal Accounting Officer
About Incyte Corporation
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company's clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.